A randomized, multicenter, open label, comparative study to evaluate the immunogenicity and reactogenicity of a new fully liquid pentavalent DTwP-Hib-IPV vaccine (EasyfourPol, Panacea Biotec Ltd.) with tetravalent DTwP/Hib vaccine (TetrAct-Hib), co-administered with Imovax Polio (Salk Based Inactivated Polio Vaccine) of sanofi pasteur India Pvt. Ltd. in Healthy Infants.

Trial Profile

A randomized, multicenter, open label, comparative study to evaluate the immunogenicity and reactogenicity of a new fully liquid pentavalent DTwP-Hib-IPV vaccine (EasyfourPol, Panacea Biotec Ltd.) with tetravalent DTwP/Hib vaccine (TetrAct-Hib), co-administered with Imovax Polio (Salk Based Inactivated Polio Vaccine) of sanofi pasteur India Pvt. Ltd. in Healthy Infants.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Sep 2016

At a glance

  • Drugs Hib-DTP-poliovirus vaccine (Primary) ; Hib-DTP vaccine; Poliovirus vaccine inactivated
  • Indications Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus
  • Focus Pharmacodynamics
  • Sponsors Panacea Biotec
  • Most Recent Events

    • 04 Mar 2011 Status changed from not yet recruiting to recruiting as reported by Clinical Trials Registry - India.
    • 24 Feb 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top